Introduction
In recent years much interest has been focused on angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension and congestive heart failure. Captopril, the first orally active ACE inhibitor, has been shown to be effective in renovascular and essential hypertension, either as monotherapy or in combination with diuretics (Vidt et al., 1982) . Along with the documented efficacy of captopril some side effects have been observed, viz., skin rashes, taste impairment, proteinuria and membranous glomerulonephritis (Vlasses et al., 1982) . Neutropenia has also been reported in patients with renal impairment treated with high doses of captopril. The side effects of captopril may be related to its chemical structure and not its ACE inhibiting activity, since they are similar to those observed with penicillamine, which also has a sulphydryl group.
A new group of nonsulphydryl containing ACE inhibitors (Patchett et al., 1980) is being evaluated clinically for the treatment of hypertension and congestive heart failure. One of these drugs, enalapril maleate (MK-421), seems to suppress the formation of angiotensin II for longer periods (Gomez et al., 1983a, Biollaz et Correspondence: Dr R. Bergstrand, Department of Medicine, Ostra Hospital, Goteborg, Sweden al., 1981) and to be more potent than captopril (Gomez & Cirillo, 1983) .
Patients with renovascular (Hodsman et al., 1983 ) and essential hypertension have been treated successfully with enalapril used either as monotherapy in doses ranging from 2.5 to 40 mg/day (Gomez et al., 1983a; Simon et al., 1983; Wilkins et al., 1983; Chrysant et al., 1983) or in combination with thiazides (Gomez et al., 1984) .
The purpose of the present study was to establish the minimally effective dose and investigate the dose-response relationship of enalapril in patients with mild to moderate essential hypertension.
Methods
Ninety-one caucasians with mild to moderate essential hypertension from two outpatient clinics in Goteborg participated in the study. Comparison between the combined enalapril doses and placebo, between placebo and other treatments, and between 40 mg and other treatments were made using contrasts of treatment means adjusted for subject and period effects. The linear and quadratic dose-response effects were tested by orthogonal contrasts of adjusted treatment means. Within-treatment tests and the pre-post weight comparison were t-tests. All tests were two-tailed and carried out at alpha = 0.05. The design did not permit analysis of any treatment-by-period interaction, but examination of the data in each period revealed consistent relationships among the treatments.
The proportions of patients controlled/ responded were analyzed using the method of Grizzle et al. (1969) 
Standing blood pressure
The standing blood pressures after 2 and 3 weeks of treatment were similar to the supine pressures. The blood pressures during the placebo period and after 2 and 3 weeks of treatment were generally greater in the standing than in the supine position, but the magnitude of changes and differences among and between treatments were similar (Table 2 ). Significant differences in standing blood pressures were observed in nearly the same instances as in the supine blood pressures.
Heart rates
Mean changes in supine and standing heart rates during enalapril treatment were all near zero and nonsignificant. Overall treatment effects, linear and quadratic effects, and differences between combined enalapril doses and placebo were all nonsignificant (P > 0.20).
Controlled andlor responding patients
There was a significant difference between the blood pressure at the end of the first and the second washout period. However, the blood pressures during the two treatment periods did 608 R. Bergstrand et al. Adverse effects Eight placebo-treated patients reported adverse effects during the randomized treatment period. One patient on enalapril 5 mg/day had mild However, 10 mg/day or more were needed to produce a satisfactory hypotensive effect; viz., a SDBP reduction > 10 mm Hg and achievement of blood pressure control (SDBP -90 mm Hg). After 3 weeks of treatment there was a significant linear dose-response relationship, and the blood pressure response in the groups on 2.5 and 5 mg/ day were significantly smaller than in the group on the highest dosage. In an earlier study, 2.5 mg did not produce a significant blood pressure reduction and 20 mg/day lowered the blood pressure to the same extent as 10 mg/day with the difference that the effect was more prolonged in the high dosage group . However, it has been shown that 2.5 mg of enalapril in a single dose blunts the effect of the blood pressure responses to exogenous angiotensin I . The present study showed that although 2.5 mg gave a statistically significant blood pressure decrease, 10 mg/day or more are needed to achieve satisfactory blood pressure reduction. It also showed that there is an increased response up to 40 mg/day and that a further response to even higher dosages may be anticipated.
The quadratic dose-response effect is a measure of curvature (departure from linearity) in the dose-response relationship. It could also indicate a levelling off of effect. The lack of any significant quadratic effect supports the linearity of the dose-response relationship across the 2.5-40 mg/day range.
A twice-a-day dosage regimen was used in this study. However, it has been observed subsequently that once-daily dosing is as effective as half the dose administered twice daily (Gomez et al., 1983a,b) . Although the relationship of dose to the 24 h blood pressure effect may be important, it could not be assessed in this study.
The number of patients with a controlled blood pressure (SDBP > 90 mm Hg) as well as the number of patients responding with at least a 10 mm Hg decrease in SDBP could only be studied during the first treatment period due to the period effect discussed above. However, about 40% of the patients were controlled and about 50% showed a significant blood pressure response on the two highest dosage levels. This agrees with the results of captopril where 47% were controlled on dosages up to 450 mg/day (Fernandez-Cruz et al., 1982) .
The combination of captopril and hydrochlorothiazide has been reported to give a synergistic blood pressure lowering response. This has also been shown for enalapril Vidt, 1984) ; therefore, coadministered diuretics may alter considerably the dose-response to enalapril.
Several studies of ACE inhibitors in essential hypertension have shown transient heart rate increases (Santucci et al., 1982) , heart rate decreases (Rabinad-Estrada et al., 1982) or no change in heart rates (Stumpe et al., 1982) . In the present study no change in heart rate was observed, although theoretically an increase in heart rate would be anticipated due to the vasodilating effect of enalapril. However, it has been shown that enalapril does not influence the sympathetic nervous system (Millar et al., 1982; Ibsen et al., 1983) . The lack of heart rate increase is unclear, but it has been suggested that it might be due to an increased parasympathetic activity during treatment with ACE inhibitors (Ibsen et al., 1983; Reid et al., 1983) .
In conclusion, enalapril was associated with an increasing dose-response relationship across the 2.5-40 mg/day range. The 2.5 mg/dose is effective in some patients; however, doses 3 10 mg/day may be necessary to achieve satisfactory blood pressure control.
